Initial treatment approaches and risk of transformation
| Factor . | Patients, n (%) . | Overall confirmed transformation rate, % . | Confirmed transformation adjusted HR* (95% CIs) . | Overall confirmed or suspected transformation rate, % . | Confirmed or suspected transformation adjusted HR* (95% CIs) . |
|---|---|---|---|---|---|
| Observed patients | 555 (21) | 7.6 | 1 | 17.8 | 1 |
| Treated patients | 2097 (79) | 6.2 | 0.57 (0.39-0.83) | 13.4 | 0.58 (0.46-0.75) |
| R-CVP | 300 (11) | 6.3 | 1 | 13.3 | 1 |
| R-CHOP | 641 (24) | 6.2 | 0.83 (0.46-1.50) | 13.3 | 0.94 (0.62-1.42) |
| Chemotherapy without rituximab | 71 (3) | 8.5 | 1 | 18.3 | 1 |
| Chemotherapy with rituximab | 1284 (48) | 6.5 | 0.82 (0.33-2.07) | 13.4 | 0.61 (0.34-1.11) |
| Observation† | 609 (23) | 4.9 | 1 | 13.0 | 1 |
| Rituximab maintenance† | 529 (20) | 4.5 | 0.87 (0.50-1.52) | 9.2 | 0.67 (0.46-0.97) |
| Factor . | Patients, n (%) . | Overall confirmed transformation rate, % . | Confirmed transformation adjusted HR* (95% CIs) . | Overall confirmed or suspected transformation rate, % . | Confirmed or suspected transformation adjusted HR* (95% CIs) . |
|---|---|---|---|---|---|
| Observed patients | 555 (21) | 7.6 | 1 | 17.8 | 1 |
| Treated patients | 2097 (79) | 6.2 | 0.57 (0.39-0.83) | 13.4 | 0.58 (0.46-0.75) |
| R-CVP | 300 (11) | 6.3 | 1 | 13.3 | 1 |
| R-CHOP | 641 (24) | 6.2 | 0.83 (0.46-1.50) | 13.3 | 0.94 (0.62-1.42) |
| Chemotherapy without rituximab | 71 (3) | 8.5 | 1 | 18.3 | 1 |
| Chemotherapy with rituximab | 1284 (48) | 6.5 | 0.82 (0.33-2.07) | 13.4 | 0.61 (0.34-1.11) |
| Observation† | 609 (23) | 4.9 | 1 | 13.0 | 1 |
| Rituximab maintenance† | 529 (20) | 4.5 | 0.87 (0.50-1.52) | 9.2 | 0.67 (0.46-0.97) |
Adjusted for age, stage, ECOG, B symptoms, nodal sites, extranodal sites, LDH, histologic grade, and hemoglobin. Rituximab maintenance comparison additionally adjusted for frontline treatment.
Patients with at least a response of stable disease to an initial rituximab-based regimen who were followed at least 215 days after the end of induction without experiencing progressive disease or starting a subsequent therapy within this time frame were included in analysis.